GPX3 and cardiac hypertrophy: The authors posit that aberrant methylation of the GPX3 promoter impairs the efficacy of GPX3, leading to cardiomyocyte damage owing to incomplete removal of oxygen produced by cardiac hypertrophy, DCM, and myocarditis associated with heart failure.